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Bacteria producing Klebsiella pneumoniae carbapenemases (KPCs) are rapidly emerging as a cause of multidrug-resistant infections
worldwide. KPCs enzyme are plasmid-borne and can accumulate and transfer resistance determinants to other classes of antibiotics.We report two
cases of KPC-2 carbapenemase-producing Klebsiella pneumoniae isolates from Cystic Fibrosis patients.
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1. IntroductionRespiratory infections remain a major threat to Cystic
Fibrosis (CF) patients. Although a few typical bacteria are
traditionally involved in CF lung infections, including Staph-
ylococcus aureus and Pseudomonas aeruginosa, CF patients
are susceptible to infection by other opportunistic bacterial
species that are not usually pathogenic for healthy individuals,
such as members of the Burkholderia cepacia complex,
Stenotrophomonas maltophilia and Achromobacter xylosoxi-
dans. Species of Enterobacteriaceae are not chronic colonizers
of the CF patient's airways and appear to play only a minor role
in lung infection of these patients [1].
The emergence and spread of carbapenem-resistant Enter-
obacteriaceae poses a major clinical and public health challenge.
Of special concern are organisms that produce K. pneumoniae
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doi:10.1016/j.jcf.2010.12.003carbapenem resistance mediated by KPC production is increasing
and is widespread in several regions around the world [2–5],
including Brazil [6–9]. KPC may confer low-level carbapenem
resistance, and the failure to identify this resistance with
susceptibility methods has been reported. The gene encoding
the KPC enzyme is usually flanked by transposon-related
sequences and has been identified on conjugative plasmids;
therefore, the potential for dissemination is significant [10]. These
KPC-producing bacteria are predominantly involved in nosoco-
mial infections [11]. To our knowledge, this is the first report of
carbapenemaseKPC-2-producingK. pneumoniae recovered from
two CF patients.2. Case report
Case 1: 22 years old, female, born in Rio de Janeiro, Brazil.
She presented cough dyspnoea since shewas 4 months old, but no
pneumonia or other infections.When she was 14 years old, due to
low weight gain and some episodes of cough and dyspnoea, she
was submitted to thoracic X ray which showed persistentd by Elsevier B.V. All rights reserved.
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started which revealed: 2 positive sweat tests, sputum with P.
aeruginosa and steatorrhea (fat loss: 15 g/24 h). Her pulmonary
function test revealed FEV1: 69% and FVC: 87% and the thoracic
high resolution CT showed bilateral peribronchial thickening and
cilindrical bronchiectasis. Mutation analysis identified the
following alteration: G85E/1717-1A. Treatment was started
with nutritional support, pancreatic enzymes, vitamins, alpha
dornase, bronchodilators, azithromycin, physiotherapy and anti-
biotics directed to P. aeruginosa. Inhaled tobramycin was started
when she was 15 years old. Although she had good compliance to
treatment and achieved an excellent nutritional status, she still had
frequent respiratory exacerbations, which required either oral
(ciprofloxacin) or IV antibiotics (ceftazidime and amicacyn). She
had never used carbapenems. In August 2009, she had an upper
airway infection followed by another respiratory exacerbation. At
this moment, K. pneumoniae was isolated for the first time,
together with P.aeruginosa. She started on ciprofloxacin for
21 days. The patient required inhaled colistin, when she was not
using tobramycin to achieve clinical stability.
Case 2: 17 years old, female, born in Rio de Janeiro, Brazil.
She presented failure to thrive and wheezing since she was
2 months old, but no pneumonia or other infections. When she
was 20 months old she had retal prolapse, steatorrhea and low
weight gain. CF investigation was started (at 2 years of age) and
revealed: 2 positive sweat tests, mutation analysis: ΔF508/S4X,
sputumwith P. aeruginosa and steatorrhea (fat loss: 57.8 g/24 h).
Treatment was started with nutritional support, pancreatic
enzymes, vitamins, bronchodilators, physiotherapy and antibio-
tics directed to P. aeruginosa. Alpha dornase and inhaled
tobramycin were started when she was 15 years old. She did
not have good compliance to treatment nor achieved a good
nutritional status. Respiratory exacerbations required the use of
IV antibiotics (ceftazidime, amycacin and oxacilin) twice
(January and July) in 2009. In August 2009, she had another
respiratory exacerbation and started on IV antibiotics (ceftazidime
and amicacyn) for 14 days. She had never used carbapenems. The
sputa culture performed at this period showed S. aureus, P.
aeruginosa and K. pneumoniae for the first time.
Using a disk diffusion test, both K.pneumoniae isolates were
found to be resistant to ceftazidime, cefepime, cefotaxime,
aztreonam, ciprofloxacin, piperacillin-tazobactam, ampicillin-
sulbactam, aztreonam, gentamicin and tobramycin, and were
susceptible to amikacin, imipenem (IPM) and meropenem
(MER). Isolates from case 1 and case 2 were intermediate andTable 1
Characteristic of Klebsiella pneumoniae strains isolated from two Cystic Fibrosis pa
Case Modified
Hodge
test
KPC
PCR
Amplification
and
sequencing
Disk diffusi
IMP a
1 + + blaKPC2 24 (S)
2 + + blaKPC2 25 (S)
a Imipenem.
b Ertapenem.
c Meropenem.resistant to ertapenem (ERT), respectively [12]. By the disc-
approximation test both isolates were ESBL producers and were
positive in the modified Hodge test [13]. Additionally the MICs
to IPM, MER and ERT were determined by using Etest® strips
following standard procedures (AB Biodisk, Solna, Sweden).
Both isolates exhibited susceptibility to IPM andMER and were
resistant to ERT (isolate 1 MIC=1ug/mL and isolate 2
MIC=3.0 ug/mL) using criteria defined by CLSI [12]
(Table 1). The strains demonstrated the presence of the
blaKPC-2 gene by PCR amplification [9] and sequencing of the
amplicons produced [14]. Molecular typing was performed by
pulsed-field gel electrophoresis (PFGE) [9]. This revealed that
the isolates belong to the same clonal type.
3. Discussion
We report for the first time two CF patients who were
colonized with KPC-2-producing K. pneumoniae. The isolates
belong to the same clonal type suggesting cross infection. In
subsequent respiratory cultures performed in 2010, we did not
observe the isolation of any carbapenem resistant Enterobacteria.
In general, the isolation of Enterobacteriaceae species is believed
to be a transient event and is not associated with severe disease in
CF patients. Nevertheless, even in rare occasions, the isolation of
species that produce the KPC enzyme in CF patients could have
an important impact on therapeutic management. Treatment
options are very limited because most isolates are panresistant.
Colistin seems to be an alternative choice, but its use could pose a
problem because this drug may be associated with severe
nephrotoxicity and there is a paucity of data on clinical outcomes
[15]. Moreover, K. pneumoniae really acts like a reservoir of
genetic transferable elements that may confer this type of
resistance [16]. There is a real possibility that the transmissible
KPC-2-encoding plasmid could be spread amongst different
genus [6]. Although these enzymes are frequently identified
among Enterobacteriaceae, the number of reports regarding KPC-
producing P.aeruginosa have been increasing [17–19]. P.
aeruginosa is a common cause of chronic pulmonary infection
in CF patients and contributes considerably to morbidity and
mortality through an intense host inflammatory response leading
to an irreversible loss of lung function [20]. In our report, both
patients were chronically infected by P. aeruginosa but until now
the isolates were susceptible to carbapenems. This report provides
evidence that Enterobacteria with decreased susceptibility to
carbapenem can be isolated also from CF patients. Carefultients.
on testing MIC (μg/mL)
ERTb MERc IPMa ERTb MERb
20 (S) 23 (S) 0.38 (S) 1.0 (R) 0.25 (S)
18 (I) 23 (S) 0.38 (S) 3.0 (R) 0.38 (S)
142 R.S. Leão et al. / Journal of Cystic Fibrosis 10 (2011) 140–142detection and identification of the resistance phenotypes can have
a huge impact on the protocols for patient care and microbiolog-
ical procedures.
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